Medtronic announces encouraging data from heart failure study Equities.com BLOCK HF shows a 27% relative risk reduction in the composite of death and healthcare utilization visits requiring intravenous (IV) heart failure therapy among this patient population. The CRT devices used in the BLOCK HF trial are not approved by the ... |
